Inferra AIResearch Tools

Inferra AI / Company / ABBV

AbbVie

ABBV · Health Care

Last earnings Oct 30, 2026

Key results

Reports Third-Quarter EPSquarter

$0.10

Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Percent Adjusted EPSquarter

$1.86

Percent Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR D and Milestones

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Delivers Third-Quarter Net revenuequarter

$15.776 Billion

Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Global Skyrizi Net revenuequarter

$4.708

Basis Global Skyrizi Net Revenues Were $4.708

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Global Rinvoq Net revenuequarter

$2.184

Billion Global Rinvoq Net Revenues Were $2.184

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Global Humira Net revenuequarter

$993 Million

Billion Global Humira Net Revenues Were $993 Million Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Third-Quarter Global Net revenuequarter

$2.841 Billion

Billion Global Humira Net Revenues Were $993 Million Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Global Vraylar Net revenuequarter

$934 Million

Basis Global Vraylar Net Revenues Were $934 Million

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Botox Therapeutic Net revenuequarter

$985 Million

Global Botox Therapeutic Net Revenues Were $985 Million Combined Global Ubrelvy and

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

AI analysis

Q3 2025 · reported Oct 31, 2025

Based on: Earnings release + parent 8-K — transcript not held

Reports Third-Quarter EPS · Q3 2025
$0.10
EX-99 · Oct 31, 2025
Percent Adjusted EPS · Q3 2025
$1.86
+257.7% vs prior quarter computed from stated figures
EX-99 · Oct 31, 2025
Delivers Third-Quarter Net revenue · Q3 2025
$15.776B
EX-99 · Oct 31, 2025
Global Skyrizi Net revenue · Q3 2025
$4.708
+6.4% vs prior quarter computed from stated figures
EX-99 · Oct 31, 2025

The quarter in charts

Segment mix

Business-unit revenue, as stated

06.6713.320$15.776BDelivers Third-Quarter Net$2.841BGlobal Net$993MGlobal Humira Net$985MBotox Therapeutic Net$934MGlobal Vraylar Net

Segment revenue figures as stated in the event record.

Headline figures

MetricQ3 2025Prior qtrYear ago
Reports Third-Quarter EPS$0.10$0.52—
Percent Adjusted EPS$1.86$0.52—
Delivers Third-Quarter Net revenue$15.776 Billion——
Global Skyrizi Net revenue$4.708$4.423—
Global Rinvoq Net revenue$2.184$2.028—
Global Humira Net revenue$993 Million$1.180 Billion—
Third-Quarter Global Net revenue$2.841 Billion——
Global Vraylar Net revenue$934 Million$900 Million—

EX-99 · Oct 31, 2025

Guidance · company-stated

Direction: Raised

EPS

“4 Full-Year 2025 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR D and milestones expense incurred year-to-date through the third quarter 2025.”

Company outlook — Raised

“Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Company Declares dividend5.5 Percent
Dividend$1.64

Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

EPS: “4 Full-Year 2025 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR D and milestones expense incurred year-to-date through the third quarter 2025.”

Company outlook — Raised (“raising”)
“Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.”

EPS — Raised (“raising”)
“4 Full-Year 2025 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR D and milestones expense incurred year-to-date through the third quarter 2025.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Company Declares Dividend Increase of 5.5 Percent AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.64 per share to $1.73 per share beginning with the dividend payable on February 17, 2026 to shareholders of record as of January 16, 2026.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

This reflects an increase of approximately 5.5 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Since the company's inception in 2013, AbbVie has increased its quarterly dividend by more than 330 percent.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

AbbVie is a member of the S P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Strategy & priorities

We are also making great progress advancing our pipeline and investing in innovation to support AbbVie s long-term growth, said Robert A.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Allergan Aesthetics announced several marketing initiatives, which include a new national, multichannel, campaign highlighting Botox Cosmetic s (onabotulinumtoxinA) market leadership, legacy and real-world patient experiences the launch of a consumer education campaign that is aimed at providing clear, factual information about hyaluronic acid (HA) injectable fillers and the natural-looking results they can achieve and the launch of SkinVive by Juvederm into 35 new markets.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

The company also announced the start of construction on a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Risks & headwinds

About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Litigation matters primarily include charges related to actual and potential settlements of litigation.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

What changed vs prior quarter

Guidance direction — prior quarter: Raised; this quarter: Raised

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Percent Adjusted EPS — prior quarter passage and this quarter's passage are both cited.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Global Skyrizi Net revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗AbbVie — Earnings release (8-K exhibit)EX-99Oct 31, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

69 documents

Earnings releases

21 documents

Presentations

none published

Checked — this company publishes no earnings presentation. Checked 2026-10-20 (browser-verified): AbbVie publishes no earnings deck — its latest earnings event lists only the press release PDF and a pipeline-update PDF.

Transcripts

0 documents

No transcripts for AbbVie are held in this edition of the library.

Mentioned by

8 companies

Other tracked companies whose held documents mention AbbVie by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.